The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Key factors in the rising cost of new drug discovery and development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
National Conference of State Legislatures
(2011) · Reference Reviews · doi:10.1108/09504121111114072 · Cited by 2,315
Cost of innovation in the pharmaceutical industry
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90001-4 · Cited by 754
Risks in new drug development: Approval success rates for investigational drugs
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115446 · Cited by 450
Returns on Research and Development for 1990s New Drug Introductions
Grabowski, H., Vernon, J., & DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00002 · Cited by 311
A New Look at the Returns and Risks to Pharmaceutical R&D
Grabowski, H., & Vernon, J. (1990) · Management Science · doi:10.1287/mnsc.36.7.804 · Cited by 286
New drug development in the United States from 1963 to 1999
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115132 · Cited by 251
DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00001 · Cited by 233
Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS
Lichtenberg, F. R. (2001) · Health Affairs · doi:10.1377/hlthaff.20.5.241 · Cited by 214
(1998) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-1998-159 · Cited by 191
Success rates for new drugs entering clinical testing in the United States
DiMasi, J. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90066-7 · Cited by 184
Longer Patents for Increased Generic Competition in the US
Grabowski, H. G., & Vernon, J. (1996) · PharmacoEconomics · doi:10.2165/00019053-199600102-00017 · Cited by 140
Health Care For The Elderly: How Much? Who Will Pay For It?
Fuchs, V. R. (1999) · Health Affairs · doi:10.1377/hlthaff.18.1.11 · Cited by 135
Issues in Pharmaceutical Economics
Steele, H., & Chien, R. I. (1980) · Southern Economic Journal · doi:10.2307/1057285 · Cited by 120
Effective patent life in pharmaceuticals
Grabowski, H. G., & Vernon, J. M. (2000) · International Journal of Technology Management · doi:10.1504/ijtm.2000.002803 · Cited by 90
Evidence-Based And Value-Based Formulary Guidelines
Neumann, P. J. (2004) · Health Affairs · doi:10.1377/hlthaff.23.1.124 · Cited by 78
The Price Of Progress: Prescription Drugs In The Health Care Market
Kleinke, J. D. (2001) · Health Affairs · doi:10.1377/hlthaff.20.5.43 · Cited by 76
Benefits and Costs of Newer Drugs: An Update
Lichtenberg, F. R. (2002) · Managerial and Decision Economics · doi:10.1002/mde.1355 · Cited by 67
The Distribution of Sales Revenues from Pharmaceutical Innovation
Grabowski, H. G., & Vernon, J. (2000) · PharmacoEconomics · doi:10.2165/00019053-200018001-00005 · Cited by 66
New drug development in the United States, 1963 through 1984
Mattison, N., Trimble, A. G., & Lasagna, L. C. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.35 · Cited by 53
A closer look at the returns and risks of pharmaceutical R&D
Joglekar, P. N., & Paterson, M. L. (1986) · Journal of Health Economics · doi:10.1016/0167-6296(86)90003-2 · Cited by 39
Increasing Use Of New Prescription Drugs: A Case Study
Foote, S. M., & Etheredge, L. M. (2000) · Health Affairs · doi:10.1377/hlthaff.19.4.165 · Cited by 35
The rate of development of new drugs in the United States, 1963 through 1975
Wardell, W. M., Hassar, M., & Anavekar, S. N. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978242133 · Cited by 32
Wardell, W. M., May, M. S., & Trimble, A. G. (1982) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1982.181 · Cited by 20
Wardell, W. M., DiRaddo, J., & Trimble, A. G. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.160 · Cited by 16
Cited by
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
3D bioactive composite scaffolds for bone tissue engineering
Turnbull, G., Clarke, J., Picard, F., Riches, P., Jia, L., Han, F., Li, B., & Shu, W. (2018) · Bioactive Materials · doi:10.1016/j.bioactmat.2017.10.001 · Cited by 1,332
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Dobson, C. M. (2004) · Nature · doi:10.1038/nature03192 · Cited by 1,003
Hybrid Molecules with a Dual Mode of Action: Dream or Reality?
Meunier, B. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000843 · Cited by 929
Metadata
- Authors
- Dickson, M., & Gagnon, J. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-05
- Volume
- 3
- Issue
- 5
- Pages
- 417-429
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2044424923
- Cited by
- 498
- References
- 25
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.